TheraRadar
Data updated: Mar 29, 2026

YUVIWEL

NAVEPEGRITIDE
Approved 2026-02-27

To increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses...

Source: FDA Label
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
1
Priority Reviews
0
Years on Market

Details

Status
Prescription
First Approved
2026-02-27
Routes
SUBCUTANEOUS
Dosage Forms
INJECTION

Companies

Ascendis Pharma
Active Ingredient: NAVEPEGRITIDE

YUVIWEL Approval History

Loading approval history...

What YUVIWEL Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

YUVIWEL FDA Label Details

Pro

Indications & Usage

To increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.